Virtus Biotech Clinical Trials ETF
BBC
22 hedge funds and large institutions have $20.9M invested in Virtus Biotech Clinical Trials ETF in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 3 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more capital invested
Capital invested by funds: $19M → $20.9M (+$1.89M)
5% more funds holding
Funds holding: 21 → 22 (+1)
2.45% more ownership
Funds ownership: 40.35% → 42.8% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
+$1.25M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$434K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$150K |
| 4 |
Morgan Stanley
New York
|
+$111K |
| 5 |
LPL Financial
San Diego,
California
|
+$42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$635K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$312K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$37.8K |
| 4 |
BRC
BHF RG Capital
Scottsdale,
Arizona
|
-$23.4K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$9.57K |
BBC Hedge Fund Activity: Q1 2021 in Review
22 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech Clinical Trials ETF (BBC) for Q1 2021, worth a combined $20.9M — up 9.9% from $19M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBC positions and 3 closed out — a net gain of 1 holder — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Fulcrum Equity Management, adding an estimated $1.25M. The largest seller was Citadel Advisors, exiting entirely with an estimated $635K sold.
- 22 institutional investors held Virtus Biotech Clinical Trials ETF (BBC) as of Q1 2021, up from 21 in Q4 2020.
- Funds reported $20.9M of Virtus Biotech Clinical Trials ETF stock for Q1 2021, up 9.9% quarter-over-quarter.
- 4 funds opened new Virtus Biotech Clinical Trials ETF positions in Q1 2021 and 3 closed out, a net change of +1 holder.
- The largest Virtus Biotech Clinical Trials ETF buyer in Q1 2021 was Fulcrum Equity Management, an estimated $1.25M added.
- The largest Virtus Biotech Clinical Trials ETF seller in Q1 2021 was Citadel Advisors, an estimated $635K sold.
Based on aggregated 13F filings for Q1 2021.